Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina
Introduction: Severe atopic dermatitis (AD) treatment is an unmet need, given the limited efficacy and safety of classical systemic treatments (CSTs). Dupilumab is a monoclonal antibody that blocks the signaling of the interleukins that mediate the inflammatory response involved in AD. Methods: the...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2020
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/27845 |
| Aporte de: |
| id |
I10-R327-article-27845 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
dermatitis, atopic biological products antibodies, monoclonal dermatitis atópica productos biológicos anticuerpos monoclonales dermatite atópica produtos biológicos anticorpos monoclonais |
| spellingShingle |
dermatitis, atopic biological products antibodies, monoclonal dermatitis atópica productos biológicos anticuerpos monoclonales dermatite atópica produtos biológicos anticorpos monoclonais Máspero, Jorge Angles, María Valeria Ardusso, Ledit Brancciforte, Milagros Castro, Carla Cruz Iturrieta, Carmen Chouela, Ezequiel De Gennaro, Mónica Silvia Fernández Bussy, Ramón Galimberti, María Laura Galimberti, Ricardo Luis Gattolin, Gabriel Luna, Paula Carolina Magariños, Gabriel Marini, Mariano Gabriel Maskin, Matías Plafnik, Romina Raimondo, Nélida Russo, Juan Pedro Sevinsky, Luis Stringa, Matías Federico Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina |
| topic_facet |
dermatitis, atopic biological products antibodies, monoclonal dermatitis atópica productos biológicos anticuerpos monoclonales dermatite atópica produtos biológicos anticorpos monoclonais |
| author |
Máspero, Jorge Angles, María Valeria Ardusso, Ledit Brancciforte, Milagros Castro, Carla Cruz Iturrieta, Carmen Chouela, Ezequiel De Gennaro, Mónica Silvia Fernández Bussy, Ramón Galimberti, María Laura Galimberti, Ricardo Luis Gattolin, Gabriel Luna, Paula Carolina Magariños, Gabriel Marini, Mariano Gabriel Maskin, Matías Plafnik, Romina Raimondo, Nélida Russo, Juan Pedro Sevinsky, Luis Stringa, Matías Federico |
| author_facet |
Máspero, Jorge Angles, María Valeria Ardusso, Ledit Brancciforte, Milagros Castro, Carla Cruz Iturrieta, Carmen Chouela, Ezequiel De Gennaro, Mónica Silvia Fernández Bussy, Ramón Galimberti, María Laura Galimberti, Ricardo Luis Gattolin, Gabriel Luna, Paula Carolina Magariños, Gabriel Marini, Mariano Gabriel Maskin, Matías Plafnik, Romina Raimondo, Nélida Russo, Juan Pedro Sevinsky, Luis Stringa, Matías Federico |
| author_sort |
Máspero, Jorge |
| title |
Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina |
| title_short |
Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina |
| title_full |
Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina |
| title_fullStr |
Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina |
| title_full_unstemmed |
Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina |
| title_sort |
analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in argentina |
| description |
Introduction: Severe atopic dermatitis (AD) treatment is an unmet need, given the limited efficacy and safety of classical systemic treatments (CSTs). Dupilumab is a monoclonal antibody that blocks the signaling of the interleukins that mediate the inflammatory response involved in AD. Methods: the clinical response of a group of patients from Argentina with severe AD and insufficient response and/or toxicity to CSTs who were treated with dupilumab before commercial availability was analyzed. EASI, SCORAD, DLQI scales and analog visual scales of pruritus and sleep were evaluated, during a median follow-up of 189 days. In addition, the incidence of adverse events was analyzed. Results: 20 patients (13 male) were included; median age: 37.5 years; median AD evolution: 20 years; atopic comorbidity: 70%. 100% had received systemic corticosteroids (serious complications: 20%). Main reasons for discontinuation of CSTs were lack of efficacy and occurrence of adverse events. All scores were significantly and steadily reduced, with identifiable clinical response at the second month of treatment. At the end of the follow-up, only 3 patients required concomitant systemic immunosuppressive treatment. Dupilumab was well tolerated, with mild and controllable adverse events. Discussion: Dupilumab is the only biological agent with high efficacy demonstrated in clinical and observational studies. In this case series, its effectiveness was confirmed in difficult-to-treat patients with severe AD and inadequate response to CSTs. The safety profile was favorable and consistent. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2020 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/27845 |
| work_keys_str_mv |
AT masperojorge analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT anglesmariavaleria analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT ardussoledit analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT branccifortemilagros analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT castrocarla analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT cruziturrietacarmen analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT chouelaezequiel analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT degennaromonicasilvia analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT fernandezbussyramon analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT galimbertimarialaura analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT galimbertiricardoluis analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT gattolingabriel analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT lunapaulacarolina analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT magarinosgabriel analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT marinimarianogabriel analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT maskinmatias analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT plafnikromina analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT raimondonelida analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT russojuanpedro analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT sevinskyluis analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT stringamatiasfederico analysisofacaseseriesofadultpatientswithsevereatopicdermatitistreatedwithdupilumabinargentina AT masperojorge analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT anglesmariavaleria analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT ardussoledit analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT branccifortemilagros analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT castrocarla analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT cruziturrietacarmen analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT chouelaezequiel analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT degennaromonicasilvia analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT fernandezbussyramon analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT galimbertimarialaura analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT galimbertiricardoluis analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT gattolingabriel analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT lunapaulacarolina analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT magarinosgabriel analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT marinimarianogabriel analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT maskinmatias analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT plafnikromina analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT raimondonelida analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT russojuanpedro analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT sevinskyluis analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT stringamatiasfederico analisisdeunaseriedecasosdepacientesadultoscondermatitisatopicaseveratratadoscondupilumabenargentina AT masperojorge analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT anglesmariavaleria analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT ardussoledit analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT branccifortemilagros analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT castrocarla analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT cruziturrietacarmen analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT chouelaezequiel analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT degennaromonicasilvia analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT fernandezbussyramon analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT galimbertimarialaura analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT galimbertiricardoluis analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT gattolingabriel analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT lunapaulacarolina analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT magarinosgabriel analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT marinimarianogabriel analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT maskinmatias analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT plafnikromina analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT raimondonelida analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT russojuanpedro analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT sevinskyluis analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina AT stringamatiasfederico analisedeumaseriedecasosdepacientesadultoscomdermatiteatopicagravetratadoscomdupilumabenaargentina |
| first_indexed |
2024-09-03T21:01:44Z |
| last_indexed |
2024-09-03T21:01:44Z |
| _version_ |
1809210203946614784 |
| spelling |
I10-R327-article-278452024-08-27T18:27:44Z Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina Análisis de una serie de casos de pacientes adultos con dermatitis atópica severa tratados con dupilumab en Argentina Análise de uma série de casos de pacientes adultos com dermatite atópica grave tratados com dupilumabe na Argentina Máspero, Jorge Angles, María Valeria Ardusso, Ledit Brancciforte, Milagros Castro, Carla Cruz Iturrieta, Carmen Chouela, Ezequiel De Gennaro, Mónica Silvia Fernández Bussy, Ramón Galimberti, María Laura Galimberti, Ricardo Luis Gattolin, Gabriel Luna, Paula Carolina Magariños, Gabriel Marini, Mariano Gabriel Maskin, Matías Plafnik, Romina Raimondo, Nélida Russo, Juan Pedro Sevinsky, Luis Stringa, Matías Federico dermatitis, atopic biological products antibodies, monoclonal dermatitis atópica productos biológicos anticuerpos monoclonales dermatite atópica produtos biológicos anticorpos monoclonais Introduction: Severe atopic dermatitis (AD) treatment is an unmet need, given the limited efficacy and safety of classical systemic treatments (CSTs). Dupilumab is a monoclonal antibody that blocks the signaling of the interleukins that mediate the inflammatory response involved in AD. Methods: the clinical response of a group of patients from Argentina with severe AD and insufficient response and/or toxicity to CSTs who were treated with dupilumab before commercial availability was analyzed. EASI, SCORAD, DLQI scales and analog visual scales of pruritus and sleep were evaluated, during a median follow-up of 189 days. In addition, the incidence of adverse events was analyzed. Results: 20 patients (13 male) were included; median age: 37.5 years; median AD evolution: 20 years; atopic comorbidity: 70%. 100% had received systemic corticosteroids (serious complications: 20%). Main reasons for discontinuation of CSTs were lack of efficacy and occurrence of adverse events. All scores were significantly and steadily reduced, with identifiable clinical response at the second month of treatment. At the end of the follow-up, only 3 patients required concomitant systemic immunosuppressive treatment. Dupilumab was well tolerated, with mild and controllable adverse events. Discussion: Dupilumab is the only biological agent with high efficacy demonstrated in clinical and observational studies. In this case series, its effectiveness was confirmed in difficult-to-treat patients with severe AD and inadequate response to CSTs. The safety profile was favorable and consistent. Introducción: El tratamiento de la dermatitis atópica (DA) severa es una necesidad insatisfecha, dada la limitada eficacia y seguridad de los tratamientos sistémicos clásicos (TSC). Dupilumab es un anticuerpo monoclonal que bloquea la señalización de las interleuquinas mediadoras de la respuesta inflamatoria involucrada en la DA. Métodos: se analizó la respuesta clínica de un grupo de pacientes de Argentina con DA severa y respuesta insuficiente y/o toxicidad a los TSC que fueron tratados con dupilumab antes de su disponibilidad comercial. Se evaluaron las escalas EASI, SCORAD, DLQI y escalas visuales analógicas de prurito y sueño, durante una mediana de 189 días de seguimiento, así como la incidencia de eventos adversos. Resultados: Se incluyeron 20 pacientes (13 varones); mediana de edad: 37,5 años; mediana de evolución de la DA: 20 años; comorbilidad atópica: 70%. El 100% habían recibido corticoides sistémicos (complicaciones graves: 20%). Los principales motivos de suspensión de los TSC fueron falta de eficacia y aparición de eventos adversos. Los puntajes de todas las escalas se redujeron significativa y sostenidamente, con respuesta clínica evidente al segundo mes de tratamiento. Al final del seguimiento, solo 3 pacientes requerían tratamiento inmunosupresor sistémico concomitante. Dupilumab fue bien tolerado, con eventos adversos leves y controlables. Discusión: el dupilumab constituye el único agente biológico con elevada eficacia demostrada en estudios clínicos y observacionales. En esta casuística, se confirmó su efectividad en pacientes con DA severa de difícil tratamiento y respuesta inadecuada a los TSC. El perfil de seguridad resultó favorable y sostenido a mediano plazo. Introdução: O tratamento da dermatite atópica (DA) grave é uma necessidade não atendida, dada a limitada eficácia e segurança dos tratamentos sistêmicos clássicos (TSC). O dupilumabe é um anticorpo monoclonal que bloqueia a sinalização das interleucinas mediadoras da resposta inflamatória envolvida na DA. Métodos: foi analisada a resposta clínica de um grupo de pacientes na Argentina com DA grave e resposta insuficiente e/ou toxicidade ao TSC que foram tratados com dupilumabe antes da disponibilidade comercial. As escalas EASI, SCORAD, DLQI e escalas visuais analógicas de prurido e sono foram avaliadas durante uma mediana de 189 dias de seguimento, bem como a incidência de eventos adversos. Resultados: 20 pacientes (13 homens) foram incluídos; idade mediana: 37,5 anos; evolução mediana da DA: 20 anos; comorbidade atópica: 70%. 100% haviam recebido corticosteróides sistêmicos (complicações graves: 20%). Os principais motivos para a suspensão do TSC foram a falta de eficácia e a ocorrência de eventos adversos. Os escores de todas as escalas foram significativamente e constantemente reduzidos, com uma resposta clínica óbvia no segundo mês de tratamento. No final do seguimento, apenas três pacientes necessitaram de tratamento imunossupressor sistêmico concomitante. O dupilumabe foi bem tolerado, com eventos adversos leves e controláveis. Discussão: O dupilumabe é o único agente biológico com alta eficácia demonstrada em estudos clínicos e observacionais. Nesse serie de casos, sua eficácia foi confirmada em pacientes com DA grave, de difícil tratamento e resposta inadequada aos TSC. O perfil de segurança foi favorável e sustentado no médio prazo. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2020-06-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text/html application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/27845 10.31053/1853.0605.v77.n2.27845 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 77 No. 2 (2020); 94-99 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 77 Núm. 2 (2020); 94-99 Revista da Faculdade de Ciências Médicas de Córdoba; v. 77 n. 2 (2020); 94-99 1853-0605 0014-6722 10.31053/1853.0605.v77.n2 spa https://revistas.unc.edu.ar/index.php/med/article/view/27845/29855 https://revistas.unc.edu.ar/index.php/med/article/view/27845/29869 Derechos de autor 2020 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |